MedTrace Logo

Treatment of Anxiety Disorders With Trigeminal Nerve Stimulation

NCT04931134 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-04-08

No results posted yet for this study

Summary

Primary objectives: The primary objective is to ascertain if trigeminal nerve stimulation is an effective treatment with high tolerability for patients with panic disorder, generalized anxiety disorder and social anxiety disorder.

Conditions

Interventions

DEVICE

Trigeminal nerve stimulation - active

Active trigeminal nerve stimulation

DEVICE

Trigeminal nerve stimulation - sham

Sham trigeminal nerve stimulation

Sponsors & Collaborators

  • Dr. Rafael Freire

    lead OTHER

Principal Investigators

  • Rafael Freire, MD PhD · Department of Psychiatry, Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2025-12-31
Completion
2026-01-31
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04931134 on ClinicalTrials.gov